Zhe Jing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhe Jing has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Cuncun Huang
Department of Internal Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine
1 shared publication - Hailong Li
Department of Internal Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine
1 shared publication - Hongwei Wang
Laboratory of Clinical Examination, Affiliated Hospital of Gansu University of Traditional Chinese Medicine
1 shared publication - Lihua Shao
Department of Internal Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine
1 shared publication - Rong Su
Department of Internal Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine
1 shared publication - Shuping Qiu
Department of Internal Medicine, First School of Clinical Medicine, Gansu University of Chinese Medicine
1 shared publication
Latest Publications
- Open Access
- 21 February 2026
- Published by Taylor & Francis in Future Science OA
- Vol. 12 (1) , 2629346
Targeting FMO3 suppresses the malignant phenotype of colorectal cancer: evidence from bioinformatics to functional experiments
Flavin-containing monooxygenase 3 (FMO3) is a key metabolic enzyme involved in endogenous metabolism; however, its role in colorectal cancer (CRC) remains poorly understood. This study aimed to investigate the expression pattern, biological function, and potential clinical relevance of FMO3 in CRC. Publicly available transcriptomic datasets were analyzed to assess FMO3 expression and its association with clinical characteristics. Immunohistochemistry and in vitro functional assays were performed to evaluate the effects of FMO3 on CRC cell proliferation, cell-cycle progression, migration, and invasion. Bioinformatics analyses were used to explore potential signaling pathways and immune-related associations. FMO3 was significantly upregulated in CRC tissues and cell lines and was associated with unfavorable clinicopathological features and poor prognosis. Silencing of FMO3 inhibited CRC cell proliferation by inducing G0/G1 cell-cycle arrest and suppressed migration and invasion by reversing epithelial-mesenchymal transition-related phenotypes. Mechanistically, FMO3 depletion attenuated PI3K/AKT signaling activity. In addition, FMO3 expression was correlated with immune cell infiltration patterns and immune checkpoint-related molecules. FMO3 promotes malignant progression of colorectal cancer and may serve as a potential biomarker and therapeutic target. Further in vivo and mechanistic studies are warranted to validate these findings.
- 21 February 2026
- Published by Taylor & Francis in Future Science OA
- Vol. 12 (1) , 2629346
Open AccessTargeting FMO3 suppresses the malignant phenotype of colorectal cancer: evidence from bioinformatics to functional experiments
Flavin-containing monooxygenase 3 (FMO3) is a key metabolic enzyme involved in endogenous metabolism; however, its role in colorectal cancer (CRC) remains poorly understood. This study aimed to investigate the expression pattern, biological function, and potential clinical relevance of FMO3 in CRC. Publicly available transcriptomic datasets were analyzed to assess FMO3 expression and its association with clinical characteristics. Immunohistochemistry and in vitro functional assays were performed to evaluate the effects of FMO3 on CRC cell proliferation, cell-cycle progression, migration, and invasion. Bioinformatics analyses were used to explore potential signaling pathways and immune-related associations. FMO3 was significantly upregulated in CRC tissues and cell lines and was associated with unfavorable clinicopathological features and poor prognosis. Silencing of FMO3 inhibited CRC cell proliferation by inducing G0/G1 cell-cycle arrest and suppressed migration and invasion by reversing epithelial-mesenchymal transition-related phenotypes. Mechanistically, FMO3 depletion attenuated PI3K/AKT signaling activity. In addition, FMO3 expression was correlated with immune cell infiltration patterns and immune checkpoint-related molecules. FMO3 promotes malignant progression of colorectal cancer and may serve as a potential biomarker and therapeutic target. Further in vivo and mechanistic studies are warranted to validate these findings.